Senate committee OKs generics bill

Share this article:
The Senate Judiciary Committee has approved the Preserve Access to Affordable Generics Act, sponsored by Herb Kohl (D-WI), that would prohibit innovator drug companies from compensating generic drug companies to delay a generic drug’s entry into the market.

The bill would make it illegal for any person, in connection with the sale of a drug product, to directly or indirectly be party to any agreement resolving or settling a patent infringement claim in which an Abbreviated New Drug Application (ANDA) filer receives anything of value. And the ANDA filer would agree not to research, develop, manufacture, market or sell the ANDA product for any period of time.

The legislation also would require the Federal Trade Commission to study:
• The prevalence of agreements in patent infringement suits;
• The impact of such agreements on drug industry competition;
• The prevalence in the drug industry of other anticompetitive agreements among competitors or other practices contrary to the antitrust laws;
• And the impact of such agreements or practices on competition in the drug market in the last five years.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.